TWILIGHT: A Randomized Trial of Ticagrelor Monotherapy Versus Ticagrelor Plus Aspirin Beginning at 3 Months in High-risk Patients Undergoing Percutaneous Coronary Intervention
A P2Y12 inhibitor-based monotherapy after a short period of dual antiplatelet therapy is emerging as a plausible strategy to decrease bleeding events in high-risk patients receiving dual antiplatelet therapy after percutaneous coronary intervention. Ticagrelor With Aspirin or Alone in High-Risk Pati...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | article |
| Language: | EN |
| Published: |
Radcliffe Medical Media
2020
|
| Subjects: | |
| Online Access: | https://doaj.org/article/00b68501fcf04b64ab484ff925adf97a |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Be the first to leave a comment!